1.48 USD
+0.01 (+0.68%)
ChartMill assigns a Buy % Consensus number of 40% to ACHL. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 6.12. This target is 313.51% above the current price.
ACHL was analyzed by 6 analysts. The buy percentage consensus is at 40. So analysts seem to be rather negative about ACHL.
In the previous month the buy percentage consensus was at a similar level.
ACHL was analyzed by 6 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-04-05 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-04-05 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2023-12-14 | B of A Securities | Downgrade | Buy -> Underperform |
| 2023-08-07 | Chardan Capital | Reiterate | Buy -> Buy |
| 2023-05-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2022-12-07 | Chardan Capital | Maintains | Buy |
| 2022-12-07 | Piper Sandler | Maintains | Overweight |
| 2021-04-26 | Chardan Capital | Initiate | Buy |
| 2021-04-26 | Oppenheimer | Initiate | Outperform |
| 2021-04-26 | JP Morgan | Initiate | Underweight |
| 2021-04-26 | B of A Securities | Initiate | Buy |
| 2021-04-26 | Piper Sandler | Initiate | Overweight |
ACHILLES THERAPEUTICS PL-ADR / ACHL FAQ
Can you provide the average price target for ACHILLES THERAPEUTICS PL-ADR stock?
6 analysts have analysed ACHL and the average price target is 6.12 USD. This implies a price increase of 313.51% is expected in the next year compared to the current price of 1.48.
Can you provide the consensus rating for ACHILLES THERAPEUTICS PL-ADR stock?
The consensus rating for ACHILLES THERAPEUTICS PL-ADR (ACHL) is 40 / 100 . This indicates that analysts generally have a neutral outlook on the stock.